Our Pipeline

Developing life-changing gene therapies for devastating diseases of the central nervous system.

Voyager’s product pipeline includes programs for advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our gene therapies will use either gene replacement or gene knockdown techniques. By significantly increasing or decreasing production of relevant proteins at targeted sites within the central nervous system, the goal is to address the underlying biology of the disease and make a meaningful difference for patients.